Adam Elsesser Sells 15,890 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN - Get Free Report) CEO Adam Elsesser sold 15,890 shares of the stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $253.40, for a total transaction of $4,026,526.00. Following the completion of the transaction, the chief executive officer directly owned 122,441 shares of the company's stock, valued at approximately $31,026,549.40. The trade was a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Adam Elsesser also recently made the following trade(s):

• On Wednesday, June 11th, Adam Elsesser sold 15,910 shares of Penumbra stock. The shares were sold at an average price of $253.67, for a total value of $4,035,889.70.
• On Wednesday, May 28th, Adam Elsesser sold 16,300 shares of Penumbra stock. The stock was sold at an average price of $267.91, for a total transaction of $4,366,933.00.
• On Wednesday, May 14th, Adam Elsesser sold 16,600 shares of Penumbra stock. The stock was sold at an average price of $298.22, for a total value of $4,950,452.00.
• On Wednesday, May 7th, Adam Elsesser sold 16,650 shares of Penumbra stock. The shares were sold at an average price of $289.37, for a total transaction of $4,818,010.50.
• On Wednesday, April 16th, Adam Elsesser sold 16,560 shares of Penumbra stock. The shares were sold at an average price of $274.35, for a total value of $4,543,236.00.
• On Wednesday, April 2nd, Adam Elsesser sold 16,565 shares of Penumbra stock. The shares were sold at an average price of $272.24, for a total transaction of $4,509,655.60.

Penumbra Stock Down 0.2%

Shares of NYSE:PEN traded down $0.43 during trading on Monday, reaching $256.00. The stock had a trading volume of 262,044 shares, compared to its average volume of 505,341. The firm's 50-day simple moving average is $272.45 and its 200 day simple moving average is $268.18. The company has a current ratio of 6.30, a quick ratio of 3.68 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The company has a market capitalization of $9.91 billion, a P/E ratio of 241.51, a PEG ratio of 2.28 and a beta of 0.50.

Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.17. The company had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a net margin of 3.41% and a return on equity of 11.14%. Penumbra's revenue was up 16.3% compared to the same quarter last year. During the same period last year, the firm earned $0.41 earnings per share. As a group, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PEN. Synergy Investment Management LLC acquired a new stake in Penumbra in the first quarter worth about $27,000. First Horizon Advisors Inc. raised its position in shares of Penumbra by 404.8% in the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock valued at $28,000 after purchasing an additional 85 shares during the last quarter. Hurley Capital LLC acquired a new stake in Penumbra in the 4th quarter worth approximately $56,000. AlphaQuest LLC purchased a new stake in Penumbra during the 1st quarter worth approximately $66,000. Finally, Huntington National Bank grew its position in Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after purchasing an additional 154 shares during the last quarter. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. BTIG Research restated a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Truist Financial lifted their price objective on shares of Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Royal Bank Of Canada upped their target price on shares of Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. UBS Group reiterated a "buy" rating and issued a $330.00 price target (up previously from $320.00) on shares of Penumbra in a report on Thursday, April 24th. Finally, Robert W. Baird raised their price objective on Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Penumbra has a consensus rating of "Moderate Buy" and an average price target of $302.40.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.